B Group, Inc.

DALLAS, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$162.1M2026 Q3
Positions19
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.80.2%

B Group, Inc. reported 19 positions worth $162.1M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ADMA (20.2%). Biggest move: exit INVESCO QQQ TR ($36.8M).

10 / 19 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ADMAAdma Biologics$32.7M20.18%3,262,542——+36.4%
▸ 2 FTHFaeth Therapeutics$18.1M11.19%610,169——-66.3%
▸ 3 PALIPalisade Bio$15.4M9.50%11,414,285——-17.0%
▸ 4 NRXPNRX Pharmaceuticals$12.5M7.70%4,277,200———
▸ 5 ZLABZai Lab$11.9M7.32%450,646——-6.6%
▸ 6 PRAXPraxis Precision Medicines$9.7M5.97%33,237——+12.7%
▸ 7 SGHTSight Sciences$9.1M5.60%970,000——+15.7%
▸ 8 TSHATaysha Gene Therapies$8.8M5.41%1,800,556——-15.8%
▸ 9 IOVAIovance Biotherapeutics$6.3M3.88%425,000——-47.6%
▸ 10 GPCRStructure Therapeutics$5.6M3.47%180,000——-36.0%

Pro Feature

The remaining 9 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does B Group, Inc. hold as of Q3 2026?

B Group, Inc. reported 19 positions worth $162.1M in its Q3 2026 13F filing. Largest positions: ADMA (20.2%), FTH (11.2%), PALI (9.5%), NRXP (7.7%) and ZLAB (7.3%).

What did B Group, Inc. buy in Q3 2026?

New positions: QTTB. Added to: DRUG, GPCR and NRXP.

What did B Group, Inc. sell in Q3 2026?

Reduced: IOVA, ORKA and SYRE. Sold out entirely: INVESCO QQQ TR.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.